Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer ; volume:19 ; number:1 ; day:24 ; month:1 ; year:2019 ; pages:1-14 ; date:12.2019
BMC cancer ; 19, Heft 1 (24.1.2019), 1-14, 12.2019
- Creator
-
Mumin, Nuramalina H.
Drobnitzky, Neele
Patel, Agata
Lourenco, Luiza Madia
Cahill, Fiona F.
Jiang, Yanyan
Kong, Anthony
Ryan, Anderson J.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-019-5295-z
- URN
-
urn:nbn:de:101:1-2019030120331469779441
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:53 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mumin, Nuramalina H.
- Drobnitzky, Neele
- Patel, Agata
- Lourenco, Luiza Madia
- Cahill, Fiona F.
- Jiang, Yanyan
- Kong, Anthony
- Ryan, Anderson J.
- SpringerLink (Online service)
Other Objects (12)
HSP90 is essential for Jak-STAT signaling in classical Hodgkin lymphoma cells
HSP90 promotes tumor associated macrophage differentiation during triple-negative breast cancer progression
A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response
Modeling Heterogeneity of Triple‐Negative Breast Cancer Uncovers a Novel Combinatorial Treatment Overcoming Primary Drug Resistance
Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms
HSP90 inhibitors disrupt a transient HSP90-HSF1 interaction and identify a noncanonical model of HSP90-mediated HSF1 regulation
Co-delivery of Gefitinib and chloroquine by chitosan nanoparticles for overcoming the drug acquired resistance
DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy
Intracellular signal transduction: the JAK-STAT pathway
JAK/STAT in leukemia: a clinical update
Phosphoregulation des Hsp90-Chaperonsystems
HSP90 is essential for Jak-STAT signaling in classical Hodgkin lymphoma cells
HSP90 promotes tumor associated macrophage differentiation during triple-negative breast cancer progression
A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response
Modeling Heterogeneity of Triple‐Negative Breast Cancer Uncovers a Novel Combinatorial Treatment Overcoming Primary Drug Resistance
Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms
HSP90 inhibitors disrupt a transient HSP90-HSF1 interaction and identify a noncanonical model of HSP90-mediated HSF1 regulation
Co-delivery of Gefitinib and chloroquine by chitosan nanoparticles for overcoming the drug acquired resistance
DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy
Intracellular signal transduction: the JAK-STAT pathway
JAK/STAT in leukemia: a clinical update
Phosphoregulation des Hsp90-Chaperonsystems
HSP90 is essential for Jak-STAT signaling in classical Hodgkin lymphoma cells
HSP90 promotes tumor associated macrophage differentiation during triple-negative breast cancer progression
A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response
Modeling Heterogeneity of Triple‐Negative Breast Cancer Uncovers a Novel Combinatorial Treatment Overcoming Primary Drug Resistance
Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms
HSP90 inhibitors disrupt a transient HSP90-HSF1 interaction and identify a noncanonical model of HSP90-mediated HSF1 regulation
Co-delivery of Gefitinib and chloroquine by chitosan nanoparticles for overcoming the drug acquired resistance
DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy
Intracellular signal transduction: the JAK-STAT pathway
JAK/STAT in leukemia: a clinical update